Hepatitis vaccines are essential tools in preventing viral infections that target the liver, specifically Hepatitis A and Hepatitis B. The Hepatitis A vaccine is vital for safeguarding against contamination-related infections, commonly transmitted through contaminated food or water. It is particularly recommended for travelers to regions with a higher prevalence of Hepatitis A. The Hepatitis B vaccine is a key component in preventing chronic Hepatitis B infections, which can lead to severe liver diseases, including cirrhosis and liver cancer. Administered as part of routine childhood immunization schedules, it is also recommended for adults, especially those at an increased risk of exposure. Combined vaccines, such as the Hepatitis A and B combination, provide comprehensive protection against both viruses. Beyond individual protection, widespread vaccination efforts contribute significantly to public health by reducing the overall burden of Hepatitis-related diseases globally. Continuous research and development efforts aim to expand vaccine coverage, addressing additional Hepatitis strains and reinforcing the commitment to preventing and controlling Hepatitis infections on a global scale. Regular vaccination campaigns and healthcare initiatives remain critical in promoting broad immunization against Hepatitis.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States